Frataxin Mitochondrial (Friedreich s Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H1 2018

  • ID: 4576112
  • Report
  • 40 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Pfizer Inc
  • Voyager Therapeutics Inc
  • MORE
Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H1 2018

Summary:

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe2+ to proteins involved in these pathways. It plays a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe2+ to Fe3.

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Friedreich’s Ataxia and Cardiomyopathy.

The latest report Frataxin Mitochondrial - Pipeline Review, H1 2018, outlays comprehensive information on the Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)
  • The report reviews Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Pfizer Inc
  • Voyager Therapeutics Inc
  • MORE
Introduction

Report Coverage

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Overview

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Companies Involved in Therapeutics Development

Adverum Biotechnologies Inc

Pfizer Inc

Voyager Therapeutics Inc

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Drug Profiles

ADVM-063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGIL-FA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTI-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedreich’s Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedreich’s Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JOT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Frataxin for Friedreich’s Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VYFXN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Dormant Products

Frataxin Mitochondrial (Friedreich’s Ataxia Protein or FXN or EC 1.16.3.1) - Product Development Milestones

Featured News & Press Releases

May 18, 2018: Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting

Oct 31, 2017: Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich’s Ataxia

Aug 22, 2017: Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich’s Ataxia

Aug 03, 2017: Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich’s Ataxia

Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich’s Ataxia

Aug 05, 2015: Key Patent Granted for AAVLife’s Gene-Therapy Program to Treat Cardiomyopathy in Friedreich’s Ataxia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Adverum Biotechnologies Inc, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Voyager Therapeutics Inc, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adverum Biotechnologies Inc
  • Pfizer Inc
  • Voyager Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll